Table 5.

Multivariate analysis of factors associated with outcomes of Ph positive ALL patients with positive pre-transplantation MRD who underwent allo-SCT (n = 54).

Covariate	Univariate analysis			Multivariate analysis
	HR	95% CI	P-value	HR	95% CI	P-value
Relapse
Transplant modality (haplo-SCT vs. MSDT)*	0.288	0.093–0.895	0.031	0.288	0.093–0.895	0.031
Disease status (CR > 1 vs. CR1)	2.304	0.989–5.366	0.053
Transplant-related mortality
Platelet engraftment (yes vs. no)	0.072	0.007–0.707	0.024	0.072	0.007–0.707	0.024
Leukemia-free survival
Transplant modality (haplo-SCT vs. MSDT)	0.363	0.135–0.977	0.045	0.283	0.099–0.810	0.019
Platelet engraftment (yes vs. no)	0.090	0.019–0.428	0.002	0.056	0.011–0.293	0.001
Overall survival
Transplant modality (haplo-SCT vs. MSDT)	0.334	0.121–0.924	0.035	0.252	0.084–0.752	0.013
Platelet engraftment (yes vs. no)	0.090	0.019–0.425	0.002	0.052	0.010–0.276	0.001

MSDT, human leukocyte antigen-matched sibling donor transplantation; halo-SCT, haploidentical stem cell transplantation; HR, hazard ratio; CI, confidence interval.

^*All variables were first included in the univariate analysis, including sex, age, donor-recipient sex-matched grafts, donor-recipient relationship, ABO matched graft, transplantation modality, disease status and engraftments; only variables with P < 0.1 were included in the Cox proportional hazards model with time-dependent variable.